IRS19 - instructions for use. IRS19 - instructions for use IRS 19 repeated course
Some facts about the product:
Instructions for use
Price in the online pharmacy site: from 468
Pharmacological properties
The medical device IRS 19 is an immunostimulating drug that exhibits the properties of a local vaccine. It is used for preventive therapy and treatment of diseases occurring in the upper respiratory tract and having an acute and chronic nature. The drug is successfully used in the pediatric field.
The drug is included in the group of antibacterial vaccines due to lysates of strains of the most common pathogens included in its composition. The production process for the destruction of microorganisms is carried out in such a way as to weaken the strains, but fully preserve their properties. When the active substance interacts with the immune system of the human body, specific and non-specific protective immunity is developed. During the spraying procedure, a fine aerosol is formed that covers the mucous membranes of the nasal cavity, which contributes to the development of an immune response and forms a specific protection. Specific protective functions are due to the local formation of antibodies that are part of the secretory immunoglobulin class of type A (IgA). Antibodies prevent the processes of fixation and reproduction of infection on the mucous membranes. The properties of non-specific immune protection are an increase in the activity of phagocytes and an increase in the level of lysozyme.
The drug has an almost instantaneous effect, after the first application, the duration of protection is about two hours. After a fourteen-day therapeutic course, the protective properties remain for three to four months. The drug is well tolerated, due to which it is used in pediatric practice even in infants (from the age of three months).
When using IRS 19 in complex treatment:
- There is an inhibition of the infectious-inflammatory process at its very beginning.
- The duration of therapy with antibiotic and anti-inflammatory drugs is reduced.
- The healing process is accelerated.
- The risk of developing complications is reduced.
Indications for use
Indications for the use of the drug IRS 19 is the need for preventive therapy and treatment for the following diseases of the respiratory system and bronchial tree:
Also, the drug is used to restore the activity of local immunity after viral infections, including influenza.
In the preoperative and postoperative period during surgical interventions in the field of otolaryngology.
Contraindications
Contraindications to the use of the drug are:
- Hypersensitivity or individual intolerance to the components that make up the structure of the product.
- Diseases that are associated with dysfunctions of the immune system (autoimmune diseases).
Side effects
During the period of therapy with the medical agent IRS 19, the following negative manifestations may develop:
The immune system. In rare cases, allergic reactions may occur, manifested in redness of the skin, the development of erythema and eczema, and the occurrence of Quincke's edema.
Respiratory system. In rare cases, coughing and asthma attacks may develop.
Digestive system. There may be a feeling of nausea, vomiting, pain in the epigastric region, and disorders of the functions of the digestive system may also develop.
General. In rare cases, body temperature can rise sharply, as well as sinusitis, nasopharyngitis, laryngitis and bronchitis symptoms.
If negative effects occur, it is necessary to interrupt therapy and seek advice from a specialist doctor, who, after an examination and additional studies, will prescribe you a drug that is an analogue of the described remedy.
Dosage and method of use
The drug is used intranasally (aerosol administration by pressing the spray gun).
One dose is considered one short press.
During the procedure, you should keep the container with the medicine upright.
For preventive therapy for adult patients and children who have reached the age of three months, it is recommended to start using the remedy fourteen to twenty-one days before the expected period of general morbidity.
The dosage is the use of one standard dosage in each nostril twice a day.
The duration of the therapeutic course is fourteen days.
Therapy of diseases localized in the upper respiratory tract, acute and chronic in patients who have reached the age of three, is carried out using one standard dosage of the drug in each nostril, two to five times a day. For patients from three months to three years, the standard dosage is used twice a day.
The procedure is possible only after the removal of mucous accumulations from the nasal cavity.
The therapeutic course is carried out until the complete disappearance of the manifestations of an infectious disease.
For procedures to restore local immunity after influenza and other infectious viral diseases in adult patients and children, it is necessary to carry out procedures using one standard dosage in each nostril twice a day.
The duration of the therapeutic course is fourteen days.
When carrying out preparatory measures before surgery, as well as for use in the postoperative period, it is necessary to use the agent in one standard dosage in each nostril twice a day.
It is necessary to start a therapeutic course with the drug seven days before a planned operation.
The duration of therapy is fourteen days.
In the first days of therapy, the following reactions may develop: increased sneezing and increased secretion of mucus from the nasal cavity. Most often these are short-term symptoms, however, if the described effects do not disappear within the first few days of treatment, it is recommended to stop using the product and consult a specialist doctor for advice.
If the container with the drug is not used for a long time, it is possible to clog the opening of the nozzle with a crystallized substance. Most often, this can occur when removing the nozzle and laying it in the downward position with the upper end, without first rinsing and blowing. In order to avoid possible blockage, a few pressures on the sprayer should be applied to create pressure that clears a possible blockage. If this method is ineffective, you can lower the nozzle into warm water for five to ten minutes to dissolve the crystals.
Overdose
Currently, there is no reliable information about the negative conditions of the patient with an overdose of the active substance. However, it can be assumed that when using a dosage exceeding the maximum therapeutic amount, the side effects described above may develop.
Features of use
The drug is intended for intranasal use, other methods of using the drug are prohibited.
Before starting a therapeutic course, it is recommended to obtain an appropriate appointment from a specialist doctor and carefully read the instructions.
During the period of use of the product, it is required to comply with sanitary and hygienic standards for drugs of this type. Do not touch contaminated surfaces with the nozzle and store the product in a special container. If necessary, the nozzle can be washed with warm water.
During the first days of therapy, increased secretion of mucus from the nose and frequent sneezing may occur, this is considered a normal reaction and disappears after a few days. However, if the symptoms do not disappear, it is recommended to consult a doctor for advice.
Also, when using the drug in very rare cases, it is possible to increase body temperature. At a temperature significantly higher than normal, you should stop taking the drug and consult a doctor. However, it should be understood that an infectious-inflammatory disease can also give an elevated temperature.
In the case of the development of a manifestation of bacterial infection, it is possible to simultaneously use the agent with antibacterial drugs.
If a patient has a history of bronchial asthmatic disease, an increased development of seizures is possible. In the case of such a course of the disease, it is recommended to interrupt the therapeutic course and not to carry out procedures with similar drugs.
Before using the cylinder, it is necessary to center the nozzle and carry out a control pressure.
The container with the drug during the procedure should be kept vertically.
It is forbidden to tilt your head back during the procedure.
With regular use of the product, the nozzle can be permanently on the bottle.
With a long break in use, clogging of the outlet of the nozzle may occur. In this case, you first need to make several clicks on the spray gun in a row to create increased pressure, which will help clear the hole. If the above procedure does not work, it is recommended to lower the nozzle into warm boiled water for five to ten minutes and then rinse it.
The container with the drug must be kept at room temperature. Do not heat or freeze the vial, even if it is empty.
Do not damage the surface of the container.
Interaction with other drugs
With the development of bacterial infection, it is possible to simultaneously use the agent with antibacterial drugs.
When combined therapy with vasoconstrictor-type drugs used by the intranasal method, it is necessary to make an interval between uses. It is recommended to carry out procedures with IRS 19 no earlier than thirty minutes after vasoconstrictor drugs.
In clinical studies, no negative interactions with other drugs have been identified.
Use of the product during pregnancy and while breastfeeding
Currently, there is no reliable information about the conduct of clinical trials of the drug in women during pregnancy and the possible negative impact on the intrauterine development of the child and the health of the expectant mother.
There is no information about the possibility of penetration of the active substance into the secretion of the mammary glands. It is recommended that if the need arises to use the medication, interrupt breastfeeding.
Driving vehicles and carrying out high-precision work
The drug does not adversely affect the psychomotor functions of the human body. There are no restrictions for driving vehicles and carrying out work that requires high concentration and attention during the period of therapy.
Interaction with alcohol
Currently, there is no data on the possible development of negative manifestations with the simultaneous use of the drug with alcoholic beverages.
Storage
Instructions for use recommends storing the medical product at a temperature not exceeding twenty-five degrees Celsius. Storage should be carried out in a vertical position of the container with the drug. Freezing, overheating and damaging the cylinder is strictly prohibited.
The shelf life of the drug is thirty-six months.
Sale in the pharmacy chain
You can buy a medicine in the pharmacy network without a prescription.
Analogues
In the event of allergic reactions or in the absence of the effectiveness of the medical product, it is recommended to consult a specialist doctor who can prescribe a replacement.
An approximate list of analogues of the drug:
Broncho-munal.
Broncho wax.
Spray based on lysates of beneficial bacteria. It is used as a local immunostimulating agent. The composition of the drug is unique and helps to resist the reproduction of pathogenic flora. It can be used in children from an early age and even in pregnant women after consulting a doctor.
Dosage form
IRS 19 is an effective tool that allows you to get rid of the pathologies of the respiratory tract. The drug is of bacterial origin. It comes in the form of a nasal spray. The tool is a liquid that can be of the following colors:
- transparent;
- colorless;
- light yellow.
The liquid has a slight specific odor. The drug is available in the form of aerosol glass bottles. Their volume is 20 ml. The cylinder has a continuous valve. Together with the medicine, a nozzle for spraying is sold. All components of the drug are placed in a cardboard box.
Description and composition
The main component of the product is bacterial lysates. Once in the human body, the drug has a stimulating effect on nonspecific and specific immunity.
When the agent is sprayed, an aerosol is formed. It settles on the mucous membrane of the upper respiratory tract. This leads to a rapid stimulation of the activity of the human immune system. In the process of exposure, secretory antibodies of the IgA class are formed. They do not allow pathogens to attach to the walls of the respiratory tract and continue to spread further.
Additionally, the drug increases the activity of macrophages - cells that destroy pathogenic microorganisms and absorb them.
The action of the drug is due to the unique composition. Its main active ingredient is a bacterial lysate, consisting of:
- Streptococcus pneumoniae type;
- Streptococcus pneumoniae type II;
- Streptococcus pneumoniae type III;
- Streptococcus pneumoniae type V;
- Streptococcus pneumoniae type VIII;
- Streptococcus pneumoniae type XII;
- Haemophilus influenzae type B;
- Klebsiella pneumoniae ss pneumoniae;
- Staphylococcus aureus ss aureus;
- Acinetobacter calcoaceticus;
- Moraxella catarrhalis;
- Neisseria subflava;
- Neisseria perflava;
- Streptococcus pyogenes group A;
- Streptococcus dysgalactiae group C;
- Enterococcus faecium;
- Enterococcus faecalis;
- Streptococcus group G.
The composition of the drug includes additional substances. These include:
- sodium merthiolate;
- nerol-based flavor (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, linalyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol);
- purified water - up to 100 ml.
Pharmacological group
IRS 19 is an immunostimulating drug of bacterial origin.
Indications for use
for adults
IRS 19 can be assigned in the following situations:
- restoration of local immunity is required after a person has had the flu or other viral infections;
- for the prevention of chronic diseases of the bronchi and upper respiratory tract;
- as a preparation for the subsequent planned intervention on the ENT organs and during the course of the postoperative period;
- for the treatment of acute and chronic diseases of the bronchi and upper respiratory tract (sinusitis, rhinitis and other problems included in the category).
for kids
IRS 19 is not assigned to children who have not yet reached the age of 3 months. If the child is older than the above age, the medication is used to combat respiratory diseases.
The toxic effect of the drug on the fetus during pregnancy or during subsequent feeding has not been identified. The doctor will prescribe a drug for the treatment of acute and chronic diseases of the bronchi and upper respiratory tract, restoration of local immunity, or as preparation for surgery.
Contraindications
It is impossible to use the medicine if a person has hypersensitivity to the components that make up the drug, or if there are autoimmune diseases.
Applications and doses
for adults
The agent is administered into the body intranasally by aerosol administration. One dose is equal to one short press on the sprayer.
The dosage of the drug can vary significantly depending on the goal pursued by the person using the remedy. If IRS 19 is used for the prevention of diseases of the upper respiratory tract, the agent is administered 1 dose in each nostril 2 times a day. The duration of the course of treatment in this situation is at least two weeks. The maximum course duration is 21 days.
If IRS 19 is used to treat acute and chronic diseases of the bronchi and upper respiratory tract, the agent is injected into each nostril in one dose from 2 to 5 times a day. Treatment is carried out until the infection disappears.
If the remedy is used to restore immunity after a person has had the flu or other viral infections, the drug is used 2 times a day. 1 dose is injected into each nostril. The duration of the course of treatment in this situation is 2 weeks.
If preparation for a planned surgical intervention is carried out or recovery is carried out during the postoperative period, the agent is administered 1 dose in each nostril 2 times a day for 2 weeks. It is recommended to start the course of treatment one week before the planned operation.
for kids
If the patient is a child, the dosage is similar to the parameters observed in the treatment of an adult. An exception to the rule is the fight against acute or chronic diseases of the upper respiratory tract or bronchi. In this situation, children who have reached the age of 3 months to 3 years are prescribed one dose of the drug in each nostril. Treatment is carried out 2 times a day. The tool can be used only after the nose has been freed from the mucous discharge. Treatment is carried out until the symptoms of infection disappear. If the child is older than 3 years, the doses are set as for an adult.
for pregnant women and during lactation
The dosage and features of the use of the drug during pregnancy and lactation are determined by the doctor.
Side effects
The drug is not harmless. It can lead to a number of side effects. After using the product, you may experience:
- From the digestive system: diarrhea, nausea, abdominal pain. Symptoms are usually rare and may appear early in treatment.
- Allergic reactions: or angioedema. The side effect is usually rare.
- From the respiratory system: asthma attacks, cough. At the beginning of treatment, sinusitis may appear.
- Other side effects. An increase in body temperature up to 39 degrees Celsius for no apparent reason. Usually this effect can occur at the beginning of treatment.
Side effects are not always related to drug exposure. If a person has noticed one of the above symptoms after using IRS 19, you should immediately contact a specialist.
Interaction with other drugs
There were no cases of negative interaction of IRS 19 with other drugs. If a person has symptoms of a bacterial infection, antibiotics may be prescribed against the background of the use of the drug.
special instructions
Starting treatment with the drug, a person should be prepared for the appearance of negative reactions. So, when the remedy is used for the first time, a person may experience an increase in nasal discharge or the appearance of sneezing. This phenomenon is usually short-lived. If the reaction of the body takes a severe course, it is worth reducing the frequency of administration of IRS 19 or completely cancel the remedy.
In rare cases, during the start of treatment, there may be an increase in temperature up to 39 degrees. If such a phenomenon takes place, the use of the remedy must be immediately canceled. However, a person must clearly distinguish between the increase in temperature caused by the use of the remedy, and the effect that gives the course of the disease. If the phenomenon is accompanied by malaise, it may be associated with the development of diseases of the upper respiratory tract.
If symptoms of a bacterial infection develop, the doctor should consider prescribing antibiotics while taking IRS 19.
If the drug is prescribed to patients who suffer from bronchial asthma, an increase in attacks is possible. In this situation, it is necessary to immediately cancel the use of the drug and not resort to its help in the future. IRS 19 does not affect the ability to drive vehicles and control potentially dangerous mechanisms.
Overdose
Cases of overdose with IRS 19 were not observed.
Storage conditions
The drug should be stored out of the reach of children. The tool must be placed strictly in a vertical position. The air temperature should not exceed 25 degrees Celsius.
The shelf life of the drug is 3 years from the date of manufacture. If the period is exceeded, the use of the tool is prohibited.
During storage, the drug should be placed in a place inaccessible to sunlight. It is necessary to ensure that the cylinder does not overheat above 50 degrees Celsius. The vial should not be pierced or burned, even if the drug is not in it.
Analogues
There are no complete analogues of the IRS 19 preparation on sale, there are only its substitutes for the pharmacological group:
- Broncho-Vaxom for adults and Broncho-Vaxom for children is a Swiss preparation containing a mixture of bacterial lysates. It is available in capsules for oral administration. Dosage form for adults can be used from 12 years. Broncho-Vaxom for children is designed specifically for children aged 6 months to 12 years.
- refers to immunostimulating drugs. It is available in tablets and granules, which are used to make a solution for oral administration. The drug is used to treat and prevent infections of the upper respiratory tract in patients older than 6 months. According to the indications, the drug can be prescribed to pregnant and lactating patients when the benefit to them outweighs the potential harm to the child.
- - an immunostimulating agent used for the treatment and prevention of infectious diseases of the respiratory system. The drug contains bacterial lysate as active ingredients. This is a Swiss medicine, produced in capsules, which are allowed from the age of 12.
- P is also available in capsules by Sandoz, Switzerland. The drug is recommended for children from 6 months to 12 years of age for the prevention and treatment of infectious diseases of the respiratory system.
The price of the drug
The cost of Irs 19 is an average of 506 rubles. Prices range from 435 to 924 rubles.
Last update of the description by the manufacturer 08.08.2007
Filterable List
Active substance:
ATX
Pharmacological group
Nosological classification (ICD-10)
3D images
Composition and form of release
| Nasal spray | 100 ml |
| active substances: | |
| bacterial lysates | 43.27 ml |
| composition of bacterial lysates: | |
| Streptococcus pneumoniae type I, II, III, V, VIII, XII | 1.11 ml |
| Staphylococcus aureus ss aureus | 9.99 ml |
| Neisseria subflava | 2.22 ml |
| Neisseria perflava | 2.22 ml |
| Klebsiella pneumoniae ss pneumoniae | 6.66 ml |
| Moraxella catarrhalis | 2.22 ml |
| Haemophilus influenzae type B | 3.33 ml |
| Acinetobacter calcoaceticus | 3.33 ml |
| Enterococcus faecium | 0.83 ml |
| Enterococcus faecalis | 0.83 ml |
| Streptococcus pyogenes group A | 1.66 ml |
| Streptococcus dysgalactia group C | 1.66 ml |
| Streptococcus group G | 1.66 ml |
| Excipients: glycine - 4.25 g; sodium merthiolate - no more than 1.2 mg; flavoring based on Nerol (linalol, alpha-terpineol, geraniol, methyl anthranilate, limonene, geranyl acetate, diethylene glycol monoethyl ether, phenylethyl alcohol) - 12.5 mg; purified water - up to 100 ml |
in vials of 20 ml (60 doses); in a box 1 bottle.
Description of the dosage form
Transparent, colorless, sometimes with a yellowish tinge, liquid with a slight odor of flavor based on Nerol.
Characteristic
Complex preparation of bacterial lysates.
pharmachologic effect
pharmachologic effect- increases specific and nonspecific immunity.Pharmacodynamics
IRS ® 19 increases specific and non-specific immunity. When spraying IRS ® 19, a fine aerosol is formed, which covers the nasal mucosa, which leads to the rapid development of a local immune response. Specific protection is due to locally formed antibodies of the class of secretory immunoglobulins type A (IgA), which prevent the fixation and reproduction of infectious agents on the mucosa. Nonspecific immunoprotection is manifested in an increase in the phagocytic activity of macrophages and an increase in the content of lysozyme.
Indications for IRS ® 19
prevention of chronic diseases of the upper respiratory tract and bronchi;
treatment of acute and chronic diseases of the upper respiratory tract and bronchi (rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis), etc.;
restoration of local immunity after influenza and other viral infections;
preparation for planned surgical intervention on the ENT organs and in the postoperative period.
Contraindications
hypersensitivity to the drug or its components in history;
autoimmune diseases.
Use during pregnancy and lactation
Side effects
While taking IRS ® 19, the following side effects may occur, both related and not related to the action of the drug.
Skin reactions: in rare cases, hypersensitivity reactions (urticaria, angioedema) and skin erythema-like and eczema-like reactions are possible.
From the ENT and respiratory organs: rarely - asthma attacks and cough.
In rare cases, at the beginning of treatment, there may be an increase in body temperature (≥39 ° C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis.
Isolated cases of thrombocytopenic purpura and erythema nodosum have been described.
Interaction
Cases of negative interaction with other drugs are unknown. In the event of the appearance of clinical symptoms of a bacterial infection, it is possible to prescribe antibiotics against the background of the continued use of IRS ® 19.
Dosage and administration
intranasally, by aerosol administration of 1 dose (1 dose = 1 short press of the atomizer). When spraying the drug, you need to keep the bottle in an upright position and do not throw your head back.
For prevention adults and children from 3 months of age (2-3 weeks before the expected rise in incidence) - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks.
For the treatment of acute and chronic diseases of the upper respiratory tract and bronchi: adults and children over 3 years old - 1 dose of the drug in each nasal passage 2-5 times a day; children from 3 months to 3 years - 1 dose of the drug in each nasal passage 2 times a day (after preliminary release from the mucous discharge). Treatment is carried out until the symptoms of infection disappear.
To restore local immunity after the flu and other respiratory viral infections: adults and children - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks.
In preparation for planned surgery and in the postoperative period: adults and children - 1 dose of the drug in each nasal passage 2 times a day for 2 weeks (it is recommended to start the course of treatment 1 week before the planned surgical intervention).
At the beginning of treatment, reactions such as sneezing and increased nasal discharge may occur. As a rule, they are of short duration. If these reactions take a severe course, the frequency of administration of the drug should be reduced or it should be canceled.
If the drug is left for a long time without use, a drop of liquid may evaporate and the resulting crystals will clog the outlet of the nozzle. This phenomenon occurs most often when the nozzle is removed and placed in the packaging with the top end down next to the bottle, without first washing and drying it. When the nozzle is clogged, several clicks are made in a row so that the liquid can pass under the action of excess pressure. If this does not help, the nozzle is lowered for several minutes in warm water.
Overdose
Cases of overdose are unknown.
Precautionary measures
The use of IRS 19 ® does not affect the psychomotor functions associated with driving a car or operating machines and mechanisms.
special instructions
When prescribing drugs based on bacterial lysates for the purpose of immunostimulation to patients with bronchial asthma, asthma attacks may occur. In this case, it is recommended to stop treatment and not take drugs of this class in the future.
Precautions for use
Spray bottle:
Keep away from heat above 50 °C and from direct sunlight;
Do not pierce the vial;
Do not burn the vial, even if it is empty.
Manufacturer
Solvay Pharma, France.
Storage conditions for IRS ® 19
At a temperature of 2-8 °C (do not freeze).Keep out of the reach of children.
Shelf life of IRS ® 19
3 years.Do not use after the expiry date stated on the packaging.
Synonyms of nosological groups
| Category ICD-10 | Synonyms of diseases according to ICD-10 |
|---|---|
| J01 Acute sinusitis | Inflammation of the paranasal sinuses |
| Inflammatory diseases of the paranasal sinuses | |
| Purulent-inflammatory processes of the paranasal sinuses | |
| Sinus infection | |
| Combined sinusitis | |
| Exacerbation of sinusitis | |
| Acute inflammation of the paranasal sinuses | |
| Acute bacterial sinusitis | |
| Acute sinusitis in adults | |
| Subacute sinusitis | |
| sinusitis acute | |
| sinusitis | |
| J02.9 Acute pharyngitis, unspecified | Purulent pharyngitis |
| Lymphonodular pharyngitis | |
| Acute nasopharyngitis | |
| J03.9 Acute tonsillitis, unspecified (tonsillitis, agranulocytic) | Angina |
| Angina alimentary-hemorrhagic | |
| Angina secondary | |
| Angina primary | |
| Angina follicular | |
| Angina | |
| Bacterial tonsillitis | |
| Inflammatory diseases of the tonsils | |
| Throat infections | |
| Catarrhal angina | |
| Lacunar angina | |
| Acute angina | |
| Acute tonsillitis | |
| Tonsillitis | |
| acute tonsillitis | |
| Tonsillar angina | |
| Follicular angina | |
| Follicular tonsillitis | |
| J04 Acute laryngitis and tracheitis | Infectious and inflammatory disease of the ENT organs |
| Laryngitis | |
| Acute laryngitis | |
| Tracheitis acute | |
| Pharyngolaryngitis | |
| J06 Acute infections of the upper respiratory tract, multiple and unspecified | Bacterial infections of the upper respiratory tract |
| Bacterial respiratory infections | |
| Pain in colds | |
| Pain in infectious and inflammatory diseases of the upper respiratory tract | |
| Viral respiratory disease | |
| Viral infections of the respiratory tract | |
| Inflammatory disease of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract | |
| Inflammatory diseases of the upper respiratory tract with difficult to separate sputum | |
| Inflammatory diseases of the respiratory tract | |
| Secondary Influenza Infections | |
| Secondary infections in colds | |
| Flu conditions | |
| Difficult sputum separation in acute and chronic respiratory diseases | |
| Upper respiratory tract infections | |
| Upper respiratory tract infections | |
| Respiratory tract infections | |
| Respiratory and lung infections | |
| ENT infections | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Infectious and inflammatory diseases of the upper respiratory tract and ENT organs | |
| Infectious and inflammatory diseases of the upper respiratory tract in adults and children | |
| Infectious and inflammatory diseases of the upper respiratory tract | |
| Infectious inflammation of the respiratory tract | |
| Respiratory tract infection | |
| upper respiratory tract catarrh | |
| Catarrh of the upper respiratory tract | |
| Catarrh of the upper respiratory tract | |
| Catarrhal phenomena from the upper respiratory tract | |
| Cough in diseases of the upper respiratory tract | |
| Cough with a cold | |
| Fever with influenza | |
| SARS | |
| ORZ | |
| ARI with rhinitis | |
| Acute respiratory infection | |
| Acute infectious and inflammatory disease of the upper respiratory tract | |
| Acute common cold | |
| Acute respiratory disease | |
| Acute influenza-like respiratory disease | |
| Sore throat or nose | |
| Cold | |
| Colds | |
| Colds | |
| Respiratory infection | |
| Respiratory viral infections | |
| Respiratory diseases | |
| Respiratory infections | |
| Recurrent respiratory tract infections | |
| seasonal colds | |
| Seasonal colds | |
| Frequent colds viral diseases | |
| J10 Influenza due to an identified influenza virus | Influenza A |
| Influenza B | |
| Flu type A | |
| Flu type B | |
| J11 Influenza, virus not identified | Pain with the flu |
| Flu | |
| Influenza in the early stages of the disease | |
| Influenza in children | |
| flu condition | |
| Influenza | |
| Incipient flu condition | |
| Acute parainfluenza disease | |
| parainfluenza | |
| Parainfluenza state | |
| Influenza epidemics | |
| J30 Vasomotor and allergic rhinitis | Allergic rhinopathy |
| Allergic diseases of the upper respiratory tract | |
| Allergic diseases of the respiratory tract | |
| allergic rhinitis | |
| allergic rhinitis | |
| allergic rhinitis seasonal | |
| Vasomotor runny nose | |
| Prolonged allergic rhinitis | |
| Perennial allergic rhinitis | |
| Perennial allergic rhinitis | |
| Perennial or seasonal allergic rhinitis | |
| Perennial allergic rhinitis | |
| Runny nose vasomotor allergic | |
| Exacerbation of hay fever in the form of rhinoconjunctival syndrome | |
| Acute allergic rhinitis | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| Swelling of the nasal mucosa | |
| hay fever | |
| Persistent allergic rhinitis | |
| Rhinoconjunctivitis | |
| Rhinosinusitis | |
| Rhinosinusopathy | |
| Seasonal allergic rhinitis | |
| Seasonal allergic rhinitis | |
| hay rhinitis | |
| Chronic allergic rhinitis | |
| J31 Chronic rhinitis, nasopharyngitis and pharyngitis | Allergic rhinosinusopathy |
| Inflammation of the nasal mucosa | |
| Infectious and inflammatory diseases of the ENT organs | |
| Perennial rhinitis | |
| Ozena | |
| Sore throat or nose | |
| Rhinitis hyperplastic | |
| Rhinitis chronic | |
| Pharyngoesophagitis | |
| Chronic bacterial rhinitis | |
| J32 Chronic sinusitis | Allergic rhinosinusopathy |
| Purulent sinusitis | |
| Catarrh of the nasopharynx | |
| Catarrh of the paranasal sinuses | |
| Exacerbation of sinusitis | |
| sinusitis chronic | |
| J40 Bronchitis, not specified as acute or chronic | allergic bronchitis |
| asthmatic bronchitis | |
| Asthmoid bronchitis | |
| Bacterial bronchitis | |
| Bronchitis | |
| Bronchitis allergic | |
| Bronchitis asthmatic | |
| smoker's bronchitis | |
| Bronchitis smokers | |
| Inflammation of the lower respiratory tract | |
| Bronchial disease | |
| Qatar smoker | |
| Smokers' cough | |
| Violation of bronchial secretion | |
| Bronchial dysfunction | |
| Acute tracheobronchitis | |
| Subacute bronchitis | |
| Rhinotracheobronchitis | |
| Rhinotracheobronchitis | |
| Tracheobronchitis | |
| Chronic lung disease | |
| J42 Chronic bronchitis, unspecified | allergic bronchitis |
| Asthmoid bronchitis | |
| Bronchitis allergic | |
| Bronchitis asthmatic | |
| Bronchitis chronic | |
| Inflammatory disease of the airways | |
| Bronchial disease | |
| Qatar smoker | |
| Cough in inflammatory diseases of the lungs and bronchi | |
| Exacerbation of chronic bronchitis | |
| Recurrent bronchitis | |
| Chronic bronchitis | |
| Chronic obstructive pulmonary disease | |
| Chronical bronchitis | |
| Chronic bronchitis of smokers | |
| Chronic spastic bronchitis | |
| Z100* CLASS XXII Surgical practice | Abdominal surgery |
| Adenomectomy | |
| Amputation | |
| Angioplasty of coronary arteries | |
| Angioplasty of the carotid arteries | |
| Antiseptic skin treatment for wounds | |
| Antiseptic hand treatment | |
| Appendectomy | |
| Atherectomy | |
| Balloon coronary angioplasty | |
| Vaginal hysterectomy | |
| Crown bypass | |
| Interventions on the vagina and cervix | |
| Bladder interventions | |
| Intervention in the oral cavity | |
| Restorative and reconstructive operations | |
| Hand hygiene of medical personnel | |
| Gynecological surgery | |
| Gynecological interventions | |
| Gynecological operations | |
| Hypovolemic shock during surgery | |
| Disinfection of purulent wounds | |
| Disinfection of wound edges | |
| Diagnostic interventions | |
| Diagnostic procedures | |
| Diathermocoagulation of the cervix | |
| Long-term surgery | |
| Replacement of fistula catheters | |
| Infection during orthopedic surgery | |
| Artificial heart valve | |
| cystectomy | |
| Brief outpatient surgery | |
| Short-term operations | |
| Short term surgical procedures | |
| Cricothyrotomy | |
| Blood loss during surgery | |
| Bleeding during surgery and in the postoperative period | |
| Culdocentesis | |
| Laser coagulation | |
| Laser coagulation | |
| Laser coagulation of the retina | |
| Laparoscopy | |
| Laparoscopy in gynecology | |
| CSF fistula | |
| Minor gynecological surgeries | |
| Minor surgical interventions | |
| Mastectomy and subsequent plasty | |
| Mediastinotomy | |
| Microsurgical operations on the ear | |
| Mucogingival operations | |
| Suturing | |
| Minor surgical interventions | |
| Neurosurgical operation | |
| Immobilization of the eyeball in ophthalmic surgery | |
| Orchiectomy | |
| Complications after tooth extraction | |
| Pancreatectomy | |
| Pericardectomy | |
| The period of rehabilitation after surgical operations | |
| The period of convalescence after surgical interventions | |
| Percutaneous transluminal coronary angioplasty | |
| Pleural thoracocentesis | |
| Pneumonia postoperative and post-traumatic | |
| Preparation for surgical procedures | |
| Preparing for surgery | |
| Preparation of the surgeon's hands before surgery | |
| Preparing the colon for surgery | |
| Postoperative aspiration pneumonia in neurosurgical and thoracic operations | |
| Postoperative nausea | |
| Postoperative bleeding | |
| Postoperative granuloma | |
| Postoperative shock | |
| Early postoperative period | |
| Myocardial revascularization | |
| Resection of the apex of the tooth root | |
| Resection of the stomach | |
| Bowel resection | |
| Uterine resection | |
| Liver resection | |
| Resection of the small intestine | |
| Resection of part of the stomach | |
| Reocclusion of the operated vessel | |
| Bonding tissue during surgery | |
| Removal of stitches | |
| Condition after eye surgery | |
| Condition after surgery | |
| Condition after surgical interventions in the nasal cavity | |
| Condition after resection of the stomach | |
| Condition after resection of the small intestine | |
| Condition after tonsillectomy | |
| Condition after removal of the duodenum | |
| Condition after phlebectomy | |
| Vascular surgery | |
| Splenectomy | |
| Sterilization of the surgical instrument | |
| Sterilization of surgical instruments | |
| Sternotomy | |
| Dental operations | |
| Dental intervention on periodontal tissues | |
| Strumectomy | |
| Tonsillectomy | |
| Thoracic surgery | |
| Thoracic surgery | |
| Total gastrectomy | |
| Transdermal intravascular coronary angioplasty | |
| Transurethral resection | |
| Turbinectomy | |
| Removal of a tooth | |
| Cataract removal | |
| Removal of cysts | |
| Tonsil removal | |
| Removal of fibroids | |
| Removal of mobile milk teeth | |
| Removal of polyps | |
| Removal of a broken tooth | |
| Removal of the body of the uterus | |
| Suture removal | |
| Urethrotomy | |
| CSF fistula | |
| Frontoethmoidogaimorotomy | |
| Surgical infection | |
| Surgical treatment of chronic leg ulcers | |
| Surgery | |
| Surgery in the anus | |
| Surgical operation on the large intestine | |
| Surgical practice | |
| surgical procedure | |
| Surgical interventions | |
| Surgical interventions on the gastrointestinal tract | |
| Surgical interventions on the urinary tract | |
| Surgical interventions on the urinary system | |
| Surgical interventions on the genitourinary system | |
| Surgical interventions on the heart | |
| Surgical manipulations | |
| Surgical operations | |
| Surgical operations on the veins | |
| Surgical intervention | |
| Surgical intervention on the vessels | |
| Surgical treatment of thrombosis | |
| Surgery | |
| Cholecystectomy | |
| Partial resection of the stomach | |
| Transperitoneal hysterectomy | |
| Percutaneous transluminal coronary angioplasty | |
| Percutaneous transluminal angioplasty | |
| Bypass coronary arteries | |
| Tooth extirpation | |
| Extraction of milk teeth | |
| Pulp extirpation | |
| extracorporeal circulation | |
| Tooth extraction | |
| Extraction of teeth | |
| Cataract extraction | |
| Electrocoagulation | |
| Endourological interventions | |
| Episiotomy | |
| Ethmoidectomy |
Country of origin
FranceProduct group
Immunomodulatory drugs and immunosuppressantsImmunostimulating drug of bacterial origin
Release form
- Nasal spray 20 ml in an aerosol can. 1 bottle complete with a nozzle and instructions for use is placed in a cardboard box.
Description of the dosage form
- Transparent colorless or yellowish liquid with a slight specific odor.
Pharmacokinetics
The drug mainly acts in the upper respiratory tract; currently there are no data on the systemic absorption of the drug.Special conditions
At the beginning of treatment, in rare cases, an increase in temperature (> 39 ° C) is possible. In this case, the treatment should be canceled. However, this condition should be distinguished from an increase in body temperature, accompanied by malaise, which may be associated with the development of diseases of the upper respiratory tract. In the presence of systemic clinical signs of a bacterial infection, the advisability of prescribing systemic antibiotics should be considered. When prescribing drugs based on bacterial lysates for the purpose of immunostimulation to patients with bronchial asthma, asthma attacks may occur. In this case, it is recommended to stop treatment and not take drugs of this class in the future. Precautions for use Spray bottle: - keep away from heat above 50°C and from direct sunlight; - do not pierce the vial; - do not burn the vial, even if it is empty. The effect of the drug on the ability to drive vehicles and other mechanisms: The use of IRS® 19 does not affect the psychomotor functions associated with driving a car or driving machines and mechanisms.Compound
- For 100 ml:
- Active substances:
- bacterial lysates 43.27 ml
- Composition of bacterial lysates:
- Streptococcus pneumoniae type I 1.11 ml
- Streptococcus pneumoniae type II 1.11 ml
- Streptococcus pneumoniae type III 1.11 ml
- Streptococcus pneumoniae type V 1.11 ml
- Streptococcus pneumoniae type VIII 1.11 ml
- Streptococcus pneumoniae type XII 1.11 mg
- Haemophilus influenzae type B 3.33 ml
- Klebsiella pneumoniae ss pneumoniae 6.66 ml
- Staphylococcus aureus ss aureus 9.99 ml
- Acinetobacter calcoaceticus 3.33 ml
- Moraxella catarrhalis 2.22 ml
- Neisseria subflava 2.22 ml
- Neisseria perflava 2.22 ml
- Streptococcus pyogenes group A 1.66 ml
- Streptococcus dysgalactiae group C 1.66 ml
- Enterococcus faecium 0.83 ml
- Enterococcus faecalis 0.83 ml
- Streptococcus group G 1.66 ml
- Excipients:
- Glycine 4.25 g
- Sodium merthiolate not more than 1.2 mg
- Nerol flavor** 12.50 mg
- Purified water up to 100 ml
- ** Nerol based flavor formulation: Linalol, Alpha Terpineol, Geraniol, Methyl Anthranilate, Limonene, Geranyl Acetate, Linalyl Acetate, Diethylene Glycol Monoethyl Ether, Phenyl Ethyl Alcohol.
Irs-19 indications for use
- - Prevention of chronic diseases of the upper respiratory tract and bronchi
- - Treatment of acute and chronic diseases of the upper respiratory tract and bronchi, such as rhinitis, sinusitis, laryngitis, pharyngitis, tonsillitis, tracheitis, bronchitis, etc.
- - Restoration of local immunity after influenza and other viral infections.
- - Preparation for planned surgical intervention on the ENT organs and in the postoperative period.
- IRS® 19 can be administered to both adults and children from 3 months of age.
Irs-19 contraindications
- - Hypersensitivity to the drug or its components in history.
- - IRS® 19 should not be prescribed to patients with autoimmune diseases.
- Pregnancy and lactation:
- There is insufficient data on the potential for teratogenic or toxic effects on the fetus during pregnancy, so the use of the drug during pregnancy is not recommended.
Irs-19 side effects
- While taking IRS®19, the following side effects may occur, both related and unrelated to the action of the drug.
- Skin reactions: in rare cases, hypersensitivity reactions (urticaria, angioedema) and skin erythema-like and eczema-like reactions are possible.
- From the ENT and respiratory organs: in rare cases - asthma attacks and cough.
- In rare cases, at the beginning of treatment, there may be:
- fever (> 39 ° C) for no apparent reason, nausea, vomiting, abdominal pain, diarrhea, nasopharyngitis, sinusitis, laryngitis, bronchitis.
- Isolated cases of thrombocytopenic purpura and erythema nodosum have been described.
- If the above symptoms appear, it is recommended to consult a doctor.
drug interaction
Cases of negative interaction with other drugs are unknown. If clinical symptoms of a bacterial infection appear, antibiotics may be prescribed against the background of continued use of IRS® 19.Overdose
To date, cases of overdose of the drug IRS® 19 have not been reported.Storage conditions
- keep away from children
